NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 8,530 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 8,530 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60. Following the completion of the sale, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total value of $834,486.84.

NewAmsterdam Pharma Trading Down 3.9 %

Shares of NAMS stock traded down $0.96 on Tuesday, reaching $23.70. 507,785 shares of the stock were exchanged, compared to its average volume of 275,345. NewAmsterdam Pharma has a 1-year low of $8.90 and a 1-year high of $26.35. The firm has a 50 day moving average of $18.68 and a two-hundred day moving average of $18.60.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors have recently added to or reduced their stakes in NAMS. Geode Capital Management LLC boosted its holdings in shares of NewAmsterdam Pharma by 1.6% during the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after acquiring an additional 1,399 shares during the period. M&T Bank Corp raised its stake in NewAmsterdam Pharma by 54.1% during the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock valued at $454,000 after acquiring an additional 9,593 shares in the last quarter. Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after acquiring an additional 628,251 shares during the period. Barclays PLC increased its holdings in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after purchasing an additional 7,199 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of NewAmsterdam Pharma during the 3rd quarter worth about $187,000. Institutional investors own 89.89% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on NAMS. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Finally, Needham & Company LLC reissued a “buy” rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, November 7th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $33.80.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.